Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication
Pharmaceutics · 23.08.2024 · 16 (9) · 1111
DOI: 10.3390/pharmaceutics16091111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.08.2024. Verfasst von Xu Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Diseases transmitted by arthropod-borne viruses such as West Nile virus (WNV) and chikungunya virus (CHIKV) pose threat to global public health. Unfortunately, to date, there is no available approved drug for severe symptoms caused by both viruses. It has been reported that reverse transcriptase inhibitors can effectively inhibit RNA polymerase activity of RNA viruses. We screened the anti-WNV activity of the FDA-approved reverse transcriptase inhibitor library and found that 4 out of 27 compounds showed significant antiviral activity. Among the candidates, etravirine markedly inhibited WNV infection in both Huh 7 and SH-SY5Y cells. Further assays revealed that etravirine inhibited the infection of multiple arboviruses, including yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and CHIKV. A deeper study at the phase of action showed that the drug works primarily during the viral replication process. This was supported by the strong interaction potential between etravirine and the RNA-dependent RNA polymerase (RdRp) of WNV and alphaviruses, as evaluated using molecular docking. In vivo, etravirine significantly rescued mice from WNV infection-induced weight loss, severe neurological symptoms, and death, as well as reduced the viral load and inflammatory cytokines in target tissues. Etravirine showed antiviral effects in both arthrophlogosis and lethal mouse models of CHIKV infection. This study revealed that etravirine is an effective anti-WNV and CHIKV arbovirus agent both in vitro and in vivo due to the inhibition of viral replication, providing promising candidates for clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
- Key Laboratory of Biological Defense, Ministry of Education, Naval Medical University, Shanghai 200433, China.
ORCID-Profile: Xu Zheng, Hailin Tang
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
Zitieren
APA
Zheng, X., He, Y., Xia, B., Tang, W., Zhang, C., Wang, D., Tang, H., Zhao, P., Peng, H., & Liu, Y. (2024). Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication. Pharmaceutics, 16(9), 1111. https://doi.org/10.3390/pharmaceutics16091111
Vancouver
Zheng X, He Y, Xia B, Tang W, Zhang C, Wang D, et al. Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication. Pharmaceutics. 2024;16(9):1111. doi:10.3390/pharmaceutics16091111
BibTeX
@article{Zheng2024,
author = {Zheng, Xu and He, Yanhua and Xia, Binghui and Tang, Wanda and Zhang, Congcong and Wang, Dawei and Tang, Hailin and Zhao, Ping and Peng, Haoran and Liu, Yangang},
title = {Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {9},
pages = {1111},
doi = {10.3390/pharmaceutics16091111}
}
EUVIMED